Veozah FDA Approval History
Last updated by Judith Stewart, BPharm on May 15, 2023.
FDA Approved: Yes (First approved May 12, 2023)
Brand name: Veozah
Generic name: fezolinetant
Dosage form: Tablets
Company: Astellas Pharma US, Inc.
Treatment for: Menopausal Disorders, Hot Flashes
Veozah (fezolinetant) is a selective neurokinin 3 (NK3) receptor antagonist indicated for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause.
- Vasomotor symptoms (VMS) are common symptoms of menopause, characterized by hot flashes (also called hot flushes) and/or night sweats. VMS can have a considerable effect on a woman's comfort and sleep, leading to anxiety, irritability, loss of productivity and depression, and potentially disrupting daily activities and impacting overall quality of life.
- Veozah is a neurokinin 3 (NK3) receptor antagonist that works to reduce the frequency and severity of hot flashes by blocking neurokinin B (NKB) binding on the kisspeptin/neurokinin/dynorphin (KNDy) neuron to moderate neuronal activity in the temperature control center of the brain.
- Veozah tablets are taken orally once daily with or without food.
- Warnings and precautions associated with Veozah include elevations in hepatic transaminase concentrations. Hepatic function should be evaluated prior to initiation of treatment.
- Common adverse reactions include abdominal pain, diarrhea, insomnia, back pain, hot flashes, and hepatic transaminase elevation.
Development timeline for Veozah
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
